文献速递垂体与肾上腺疾病

对纽约市598例肢端肥大症患者癌症预测因素与发病率的 prospective、纵向研究

Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该前瞻性纵向研究纳入598例肢端肥大症患者和292例临床无功能性垂体腺瘤(CNFPA)患者,纵向测量GH/IGF-1并长期随访。肢端肥大症癌症患病率22.6%高于CNFPA的12.7%(OR=1.99,95%CI 1.34-2.97,P=.0005),标准化发病率比为1.78(1.51-1.81)vs 1.26(0.89-1.70)。IGF-1过度累积暴露是肢端肥大症癌症的预测因素(OR=1.278,95%CI 1.060-1.541,P=.01)。

要点

  • 肢端肥大症癌症患病率22.6%,高于CNFPA的12.7%(OR=1.99,95%CI 1.34-2.97,P=.0005)。
  • 肢端肥大症癌症标准化发病率比1.78(1.51-1.81),CNFPA为1.26(0.89-1.70)。
  • IGF-1过度累积暴露是肢端肥大症癌症预测因素(OR=1.278,95%CI 1.060-1.541,P=.01)。

核心结论

  • 肢端肥大症患者癌症风险增加,而CNFPA患者未见增加。
  • IGF-1过度累积暴露是肢端肥大症癌症的预测因素。
  • 数据提示肢端肥大症癌症风险与IGF-1过度的程度和持续时间相关,充分认识该风险需长期随访。

研究设计与样本

  • 前瞻性纵向研究,纳入598例肢端肥大症患者(309例男性,289例女性)和292例临床无功能性垂体腺瘤(CNFPA)患者(140例女性,152例男性),来自同一基础人群。
  • 纵向测量GH和IGF-1水平,长期随访观察结局,检验IGF-1过度累积暴露作为癌症预测因素。
  • 比较肢端肥大症与CNFPA队列的癌症患病率,并将各自癌症发病率与监测、流行病学和最终结果(SEER)数据预期值比较。

主要发现

  • 末次随访时癌症患病率:肢端肥大症22.6% vs CNFPA 12.7%(OR=1.99,95%CI 1.34-2.97,P=.0005)。
  • 癌症总体标准化发病率比:肢端肥大症1.78(95%CI 1.51-1.81)vs CNFPA 1.26(95%CI 0.89-1.70)。
  • 癌症预测因素:IGF-1过度累积暴露OR=1.278(95%CI 1.060-1.541,P=.01);从肢端肥大症诊断至癌症或末次随访年数OR=1.03(95%CI 1.004-1.057,P=.024);随访时年龄OR=1.064(95%CI 1.047-1.082,P<.001)。

临床怎么用

  • 原文未据此给出推荐。
  • 原文结论指出肢端肥大症患者癌症风险增加,IGF-1过度累积暴露是癌症预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Long-term growth hormone/insulin-like growth factor-1 (GH/IGF-1) excess could increase the risk of cancer in acromegaly, but individual levels of these hormones do not relate to this risk. OBJECTIVE: We newly investigated longitudinally-measured IGF-1 levels as a potential predictor of cancer in a large New York City acromegaly cohort. METHODS: We conducted a prospective, longitudinal study of 598 acromegaly (309 men, 289 women) and 292 clinically nonfunctioning pituitary adenoma (CNFPA) (140 women, 152 men) patients from the same underlying population. GH and IGF-1 levels were measured longitudinally and outcomes were observed during long-term follow-up. Cumulative exposure to IGF-1 excess was tested as a predictor of cancer. We compared cancer prevalence in acromegaly and CNFPA cohorts and incidence in each to that expected from Surveillance, Epidemiology, and End Results (SEER) data. RESULTS: Cancer prevalence by last follow-up was 22.6% in acromegaly and 12.7% in CNFPAs (odds ratio [OR] = 1.99 [95% CI, 1.34-2.97]) (P = .0005). Overall standardized incidence ratio for cancer was 1.78 (1.51-1.81) in the acromegaly and 1.26 (0.89-1.70) in the CNFPA cohorts. Cumulative exposure to IGF-1 excess, OR = 1.278 (1.060-1.541) (P = .01), years from acromegaly diagnosis to cancer or last follow-up, OR = 1.03 (1.004-1.057) (P = .024), and age at follow up, OR = 1.064 (1.047-1.082) (P < .001), were predictors of cancer. CONCLUSION: Cancer risk is increased in acromegaly, but not in CNFPA patients. Cumulative exposure to IGF-1 excess is a predictor of cancer in acromegaly. Our data suggest that cancer risk in acromegaly relates to the degree and duration of IGF-1 excess and that full appreciation of this risk requires long-term follow up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Freda PU, Bruce JN, Jin Z, et al. Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly. J Clin Endocrinol Metab. 2025. PMID: 38986012. doi:10.1210/clinem/dgae469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。